nach oben

Erschienen in:

24.04.2019 | Contrast Media

Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary-phase gadoxetate parenchymal liver enhancement

verfasst von: Simon Matoori, Johannes M. Froehlich, Stefan Breitenstein, Viktoria Pozdniakova, Carolin Reischauer, Orpheus Kolokythas, Dow-Mu Koh, Andreas Gutzeit

Erschienen in: European Radiology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To identify independent confounding variables of gadoxetate-enhanced hepatobiliary-phase liver MRI using multiple regression analysis.

Materials and methods

The institutional review board generally approved retrospective analyses and all patients provided written informed consent. One hundred ten patients who underwent a standardized 3.0-T gadoxetate-enhanced liver MRI between November 2008 and June 2013 were retrospectively reviewed. The gadoxetate liver enhancement normalized to enhancement in the erector spinae muscle (relative signal enhancement, SE) was related to biochemical laboratory parameters and descriptive patient characteristics (patient age, body mass index) using non-parametric univariate correlation analysis followed by a multiple linear regression model.

Results

Using univariate statistics, relative SE was inversely correlated with patient age, ALP, AST, total bilirubin, gamma-glutamyltransferase, INR, model of end-stage liver disease score, and proportionally with albumin and hemoglobin (all p < 0.01). In a multiple regression analysis, total bilirubin (p = 0.001), serum albumin (p = 0.016), and patient age (p = 0.018) were independently correlated with relative liver SE (n = 110).

Conclusion

A multiple regression analysis showed that high total bilirubin, low serum albumin, or advanced age was associated with low hepatobiliary-phase gadoxetate parenchymal liver enhancement. In these patients, the lower contrast-to-noise ratio might impair diagnostic evaluation of non-enhancing liver lesions (e.g., HCC, liver metastasis).

Key Points

• A multiple regression analysis identified independent confounding variables of hepatobiliary-phase gadoxetate liver enhancement.

• High bilirubin, low albumin, or advanced age was associated with low enhancement.

• Diagnostic evaluation might be hampered in these patients.

Nur mit Berechtigung zugänglich

Van Beers BE, Pastor CM, Hussain HK (2012) Primovist, Eovist: what to expect? J Hepatol 57:421–429CrossRef

Reimer P, Schneider G, Schima W (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14:559–578CrossRef

Giraudeau C, Leporq B, Doblas S et al (2017) Gadoxetate-enhanced MR imaging and compartmental modelling to assess hepatocyte bidirectional transport function in rats with advanced liver fibrosis. Eur Radiol 27:1804–1811CrossRef

Higaki A, Tamada T, Sone T et al (2012) Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging. Magn Reson Imaging 30:689–693CrossRef

Chen BB, Hsu CY, Yu CW et al (2014) Hepatic necro-inflammation and elevated liver enzymes: evaluation with MRI perfusion imaging with gadoxetic acid in chronic hepatitis patients. Clin Radiol 69:473–480CrossRef

Kukuk GM, Schaefer SG, Fimmers R et al (2014) Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. Eur Radiol 24:2482–2490CrossRef

Haimerl M, Verloh N, Fellner C et al (2014) MRI-based estimation of liver function: Gd-EOB-DTPA-enhanced T1 relaxometry of 3T vs. the MELD score. Sci Rep 4:5621CrossRef

Utsunomiya T, Shimada M, Hanaoka J et al (2012) Possible utility of MRI using Gd-EOB-DTPA for estimating liver functional reserve. J Gastroenterol 47:470–476CrossRef

Nakamura S, Awai K, Utsunomiya D et al (2012) Chronological evaluation of liver enhancement in patients with chronic liver disease at Gd-EOB-DTPA-enhanced 3-T MR imaging: does liver function correlate with enhancement? Jpn J Radiol 30:25–33CrossRef

10.

Chernyak V, Kim J, Rozenblit AM, Mazzoriol F, Ricci Z (2011) Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: the role of laboratory factors. J Magn Reson Imaging 34:301–309CrossRef

11.

Kobi M, Paroder V, Flusberg M, Rozenblit AM, Chernyak V (2017) Limitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hepatobiliary phase? Clin Radiol 72:55–62CrossRef

12.

Tsuda N, Okada M, Murakami T (2007) Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 42:242–247CrossRef

13.

Tsuda N, Matsui O (2010) Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi—gadoxetic acid–enhanced MR imaging. Radiology 256:767–773CrossRef

14.

Tsuda N, Matsui O (2011) Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression. Eur Radiol 21:2542–2550CrossRef

15.

Feier D, Balassy C, Bastati N, Stift J, Badea R, Ba-Ssalamah A (2013) Liver fibrosis: histopathologic and biochemical influences on diagnostic efficacy of hepatobiliary contrast-enhanced MR imaging in staging. Radiology 269:460–468CrossRef

16.

Bastati N, Feier D, Wibmer A et al (2014) Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid–enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 271:739–747CrossRef

17.

US Food and Drug Administration (2018) Eovist(R): highlights of prescribing information available via https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022090s015,201277s015lbl.pdf Accessed on 23 Jan 2019

18.

Bieze M, van den Esschert JW, Nio CY et al (2012) Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 199:26–34CrossRef

19.

Bashir MR, Gupta RT, Davenport MS et al (2013) Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging 37:398–406CrossRef

20.

Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY (2010) Added value of gadoxetic acid–enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255:459–466CrossRef

21.

Matoori S, Froehlich JM, Breitenstein S et al (2016) Age dependence of spleen- and muscle-corrected hepatic signal enhancement on hepatobiliary phase gadoxetate MRI. Eur Radiol 26:1889–1894CrossRef

22.

Katsube T, Okada M, Kumano S et al (2012) Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging. Eur J Radiol 81:1460–1464CrossRef

23.

Nishie A, Ushijima Y, Tajima T et al (2012) Quantitative analysis of liver function using superparamagnetic iron oxide- and Gd-EOB-DTPA-enhanced MRI: comparison with technetium-99m galactosyl serum albumin scintigraphy. Eur J Radiol 81:1100–1104CrossRef

24.

Wiesner R, Edwards E, Freeman R et al (2003) Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124:91–96CrossRef

25.

Verloh N, Haimerl M, Zeman F et al (2015) Multivariable analysis of clinical influence factors on liver enhancement of Gd-EOB-DTPA-enhanced 3T MRI. Rofo 187:29–35PubMed

26.

Neuschwander-Tetri BA, Clark JM, Bass NM et al (2010) Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52:913–924CrossRef

27.

Geisel D, Raabe P, Lüdemann L et al (2017) Gd-EOB-DTPA-enhanced MRI for monitoring future liver remnant function after portal vein embolization and extended hemihepatectomy: a prospective trial. Eur Radiol 27:3080–3087CrossRef

28.

Mooij MG, Schwarz UI, de Koning BAE et al (2014) Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. Drug Metab Dispos 42:1268–1274CrossRef

29.

Dowman JK, Tomlinson JW, Newsome PN (2011) Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 33:525–540CrossRef

30.

Georgiou L, Penny J, Nicholls G et al (2017) Quantitative assessment of liver function using gadoxetate-enhanced magnetic resonance imaging: monitoring transporter-mediated processes in healthy volunteers. Invest Radiol 52:111–119CrossRef

31.

Ahmed BS, Nina B, Andreas W et al (2017) Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: where are we? J Magn Reson Imaging 45:646–659CrossRef

32.

Nilsson H, Blomqvist L, Douglas L, Nordell A, Jonas E (2010) Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI. HPB (Oxford) 12:567–576CrossRef

33.

Nilsson H, Blomqvist L, Douglas L et al (2013) Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis. Br J Radiol 86:20120653CrossRef

34.

Hinrichs H, Hinrichs JB, Gutberlet M et al (2016) Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC). Eur Radiol 26:1116–1124CrossRef

Titel: Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary-phase gadoxetate parenchymal liver enhancement
verfasst von: Simon Matoori
Johannes M. Froehlich
Stefan Breitenstein
Viktoria Pozdniakova
Carolin Reischauer
Orpheus Kolokythas
Dow-Mu Koh
Andreas Gutzeit
Publikationsdatum: 24.04.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 11/2019
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-019-06179-8

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary-phase gadoxetate parenchymal liver enhancement

Abstract

Purpose

Materials and methods

Results

Conclusion

Key Points

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Key Points

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

Does three-dimensional functional infrared imaging improve breast cancer detection based on digital mammography in women with dense breasts?

Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements

Prediction of response after chemoradiation for esophageal cancer using a combination of dosimetry and CT radiomics

Variability in the decision-making process of acute ischemic stroke in difficult clinical and radiological constellations: analysis based on a cross-sectional interview-administered stroke questionnaire

Impact of iodine concentration and iodine delivery rate on contrast enhancement in coronary CT angiography: a randomized multicenter trial (CT-CON)

Lesion detection performance of an abbreviated gadoxetic acid–enhanced MRI protocol for colorectal liver metastasis surveillance

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie